Melatonin for sleep disturbances in Parkinson's disease
Melatonin for sleep disturbances in Parkinson's disease
复制标题
DOI：
10.1016/j.sleep.2005.04.004
复制
发表时间：
2005-09-01
期刊：
影响因子：
4.8
通讯作者：
Aminoff, MJ
中科院分区：
文献类型：
--
作者：
Dowling, GA;Mastick, J;Aminoff, MJ
背景和目的：许多帕金森病（PD）患者会出现睡眠相关症状。在其他人群中的研究表明，褪黑激素可以提高睡眠效率，减少夜间活动，缩短睡眠潜伏期，但很少有研究褪黑激素在PD中的使用。本研究的目的是比较两个剂量的褪黑激素安慰剂对睡眠，白天嗜睡，和功能水平的PD患者谁抱怨sleep disturbances.Patients和方法：一个多站点双盲安慰剂对照交叉试验，40名受试者完成了10周的协议。有2周筛选期、2周治疗期和1周治疗间洗脱期。夜间睡眠活动记录仪和日记进行了评估，而白天嗜睡和功能进行了评估的埃普沃思嗜睡量表（ESS），斯坦福大学嗜睡量表（SSS），和一般睡眠障碍量表（GSDS）hereafter：重复测量方差分析显示，在夜间总睡眠时间的显着改善50毫克褪黑激素治疗相比，安慰剂。有显着改善主观睡眠障碍，睡眠量，白天嗜睡在5毫克褪黑激素治疗相比，安慰剂评估的GSDS.Conclusions：虽然我们发现一个统计学显着改善活动测量的总睡眠时间50毫克褪黑激素相比，5毫克或安慰剂，这种小的改善（10分钟）可能没有临床意义。然而，在主观睡眠障碍中发现的显著改善表明，这些适度的影响可能在该患者人群中具有临床相关性。(c)2005 Elsevier B.V.保留所有权利。
Background and purpose: Many patients with Parkinson's disease (PD) experience sleep-related symptoms. Studies in other populations indicate that melatonin can increase sleep efficiency, decrease nighttime activity, and shorten sleep latency, but there has been little research on the use of melatonin in PD. The purpose of this study was to compare the effects of two doses of melatonin to placebo on sleep, daytime sleepiness, and level of function in patients with PD who complained of sleep disturbances.Patients and methods: A multi-site double-blind placebo-controlled cross-over trial was employed; 40 subjects completed the 10-week protocol. There was a 2-week screening period, 2-week treatment periods, and 1-week washouts between treatments. Nocturnal sleep was assessed by actigraphy and diaries, whereas daytime sleepiness and function were assessed by the Epworth Sleepiness Scale (ESS), Stanford Sleepiness Scale (SSS), and General Sleep Disturbance Scale (GSDS).Results: Repeated measures analysis of variance revealed a significant improvement in total nighttime sleep time during the 50 mg melatonin treatment compared to placebo. There was significant improvement in subjective sleep disturbance, sleep quantity, and daytime sleepiness during the 5 mg melatonin treatment compared to placebo as assessed by the GSDS.Conclusions: Although we found a statistically significant improvement in actigraphically measured total sleep time on 50 mg melatonin compared to 5 mg or placebo, this small improvement (10 min) may not be clinically significant. However, the significant improvement found in subjective sleep disturbance suggests that these modest effects may be clinically relevant in this patient population. (c) 2005 Elsevier B.V. All rights reserved.